preview expect posit interim look month phase
takeaway discuss alzheim kol
rise challeng initi outperform pt
weigh exposur clinic trial
takeaway opco hc day
relief sight visibl path zuranolon
analyst certif import disclosur see
manag look puls
pandem unlik slow nda file
mek combo studi offer best path clinic relev mum
takeaway opco hc day one
translat data still queue reiter outperform
weigh impact pandem oxbryta launch
note
revenu pre-announc coronaviru impact
cloudi chanc competit move perform
stick biotech fundament market turmoil
revis develop timelin car-t jockey posit
pt
andexxa save live multipl bleed scenario
inhal nitric oxid ino potenti coronaviru
downgrad under-perform hetlioz risk
potenti short-term coronaviru impact univers
second fda alert underscor need fmt altern
mid-year data could linger doubt upgrad
updat multicent aml trial readi launch
top stori week congress pass phase two multi-billion dollar aid packag battl econom effect
coronaviru among thing legisl boost support medicar medicaid fund around
pandem nevertheless congress alreadi work next stimulu bill late thursday senat releas
draft version exce total spend propos includ number healthcar provis discuss
also aid certain distress sector
research develop effort gene replac therapi grt on-going multipl year last
decad brought five approv four market product therapi address divers set diseas vari
hematolog malign ophthalm disord use differ deliveri modal demonstr clinic
benefit rang surviv improv vision preserv follow initi approv sever grt
product registration-en trial undergo regulatori review research better understand immunogen
target deliveri improv manufactur complement support regulatori environ spur grt product
bench bedsid compani rckt/ortx cover rhhbi among other cover
implement divers strategi multi-technolog platform focus pipelin acquisit partnership in-
hous manufactur believ grt segment pivot point potenti transform treatment landscap
sever rare monogen disord previous deem untreat full report publish today
mbrx report financi result see disclos intent use on-going european phase select
us phase ii registr studi aml plan file ind next-gener anthracyclin annamycin
treatment lung met view announc part strategi acceler time-to-market indic
anthracyclin wide use expand address market indic prior anthracyclin
ineffect specif expect eu studi explor dose fda maximum cumul anthracyclin
exposur threshold base primarili cardiotox anthracyclin class observ
annamycin ep revis due higher share count
preview expect posit interim look month phase ovarian cancer studi
vblt report financi re-affirmed plan interim analysi level patient end
march continu expect posit interim result base proven moa anti-angiogen agent avastin
treatment refractori ovarian cancer strong phase ii result includ overal surviv benefit phase ii
studi demonstr respons similar ovarian cancer popul base case assum respons rate
interim analysi importantli vblt continu see steadi recruit onto studi reiter plan complet
enrol end expect second interim analysi overal respons rate data reach
studi design
ceo scott braunstein discuss recent progress anticip catalyst virtual annual healthcar
confer highlight impact clinic trial minim far timelin remain
track rse pivot trial initi expect follow updat fda meet cdd
pivot marigold top-line data expect enrol complet trial
initi still expect earli dr braunstein mention oper expect proceed accordingli despit
pandem genet epilepsi trial patient use electron diari remot data collect drug suppli
remain top prioriti recent initi coverag review case studi rse view strongli
posit cash balanc provid runway maintain outperform
takeaway discuss alzheim kol
discuss current state alzheim diseas ad treatment research martin sadowski md phd professor
neurolog psychiatri biochemistri molecular pharmacolog nyu school medicin interrupt
new patient flow ad treatment impact clinic trial enrol patient visit due age-group
relat risk infect risk typic ad patient impact would greatest iv-bas trial dr sadowski remain big
propon hypothesi would recommend condit approv aducanumab safeti remain area
focu futur practic dr sadowski expect use patient limit use mild ad pend payer decis
screen begin like scan aria first year beyond discuss target tau
microglia also discuss pimavanserin outlook ad contact us replay
rise challeng initi outperform pt
initi coverag ascendi asnd outperform rate price target innov parenter
drug deliveri asnd develop pipelin candid need inject once-weekli henc offer
meaning improv once-daili version compani initi commerci opportun larg pediatr growth
hormon replac market ww us/eu regulatori submiss slate year manag
hypoparathyroid chronic form affect patient access market optimist
key upcom clinic data third achondroplasia see asnd fast-follow forg
indic develop path expect asnd outperform high-valu therapeut asset advanc toward market
ceo julia owen cfo loui arcudi discuss recent progress anticip catalyst virtual annual
healthcar confer highlight current expect impact clinic trial timelin
remain track livoletid pw zephyr pivot studi complet lplv endpoint top line
readout still expect note patient complet core period
discontinu rate patient sinc roll lte nevanimib studi two cohort on-going
top line readout still expect antagonist vm menopaus women
still expect enter clinic balanc anticip provid runway
weigh exposur clinic trial
follow report delays/postpon clinic studi recruit provid thought coverag space
exposur global pandem offer framework understand criteria clinic trial
could expos well regulatori step could see delay due disrupt criteria includ stage
develop enrol statu geograph studi locat treatment modal indic sever therapeut area studi
popul co-morbid visit frequenc analysi plan within note see pp classifi expect clinic trial
coverag univers three categori trial initi trial on-going trial read within group
trial run stratifi trial recruit patient compar trial evalu
withdraw prior financi guidanc due disrupt revis forecast
time revisit estim come week continu expect least portion cologuard volum impact
recaptur view well posit potenti rebound
takeaway opco hc day
day oppenheim co healthcar confer hc host rang compani
meet investor given ever-escal threat investor interest rapidli shift compani
forefront develop therapi viru like regeneron investor also focus
biotech compani meaning clinic catalyst next month mention day note
catabasi catb sunesi snss celsion clsn specif wonder compani see
relat slowdown convers believ compani well set-up execut multipl front
kevzara antibodi cocktail treatment sever infect compani like catb snss clsn
see minor delay import clinic readout
spoke manag sidelin virtual oppenheim healthcar confer posit
surpris hear manag support commun clinic updat june either medic meet eha
press releas meet postpon view compani lead program etb
treatment r/r refractori dlbcl show-m stori view interim updat june suggest path respons
rate could posit catalyst share addit reiter commit busi
develop may disrupt prospect new busi develop lead manag alreadi
activ discuss sever potenti partner matur discuss impact corpor travel
restrict relat least yet
spoke manag sidelin virtual oppenheim healthcar confer would note
strong balanc sheet cash end septemb forecast oper burn
around govern contract va account revenu insul econom
slowdown logist disrupt associ due long turnaround time govern contract
manag expect comment impact oper statu discuss potenti new
pharmaceut custom earn result call remain one top pick base strong
manag healthi balanc sheet fund oper posit cash flow fundament healthi end-market
sell analyt complex diagnost test servic drug compani use oncolog drug develop
host manag vinc anido ceo rich rubino cfo oppenheim
virtual healthcar confer share item interest remind market two ophthalm drug
novel mechan action reduc intra-ocular pressur glaucoma ocular hypertens patient continu
view year commerci execut remain key focu investor howev note aeri pipelin
ou glaucoma opportun especi japan could begin get attent late year
digit annual oppenheim healthcar confer hc opportun speak aurinia
receiv updat corpor progress backdrop pandem auph continu execut pre-
commerci activ voclosporin includ recent initi roll nda submiss establish commerci
oper center key commerci hire
broader market weak place pressur share view compani pre-commerci stage well-
posit weather evolv paradigm biotech univers believ combin strong fundament
science/clin evid medium-term commerci revenu opportun clinic pipelin catalyst strong balanc
sheet million lend well auph stori stay bullish
relief sight visibl path zuranolon
provid long-await clariti next-step zuranolon follow disappoint result
mountain trial mdd read-out plan pursu three distinct indic zuranolon
new mother acut rapid respons therapi arrt co-administ ssri mdd episod therapi mdd
origin plan requir one addit trial plan initi top-line data still
expect shorelin top-line data amend protocol includ cohort continu paus
redwood rainforest trial priorit expediti path zuranolon continu develop
earlier-stag pipelin updat model new prior
ceo rohan palekar cfo ryan martin discuss recent progress anticip catalyst virtual
annual healthcar confer highlight impact clinic trial minim far
timelin still track nash trial enrol remain on-going top-line data still expect
shtg studi initi still expect top-line data competit landscap nash
continu evolv recent aldafermin analog data provid posit read-through moa
provid evid correl mri-pdff liver fat reduct improv histolog
remain well-posit financi follow ipo estim cash recent initi coverag
remain confid dual strategi pursu nash shtg potenti best-in-class
ceo jay luli discuss recent progress anticip catalyst virtual annual healthcar confer
highlight recent work began identifi candid potenti antivir therapi
rsvp data expect addit rsv studi initi studi move southern
hemispher follow rsv infect blunt potenti impact nash trial
initi pbc intrepid data expect follow-on fxr-agonist nash studi
initi core-inhibitor hbv data support dose addit studi
viremic-hbv patient initi
host manag todd basemor brazzel oppenheim
virtual healthcar confer share item interest remind market invelti post-ocular
inflamm pain also recent announc registr enabl eysuvi phase data temporari relief dri
eye diseas view eysuvi regulatori approv like year-end subsequ commerci launch key valu
drive event stock near-term
clinic develop claudin prows svp corp dev strategi oppenheim virtual healthcar confer
share item interest remind track two import clinic catalyst could
unlock meaning valu first-in-human data patient enrol two dose cohort danon diseas
preliminari data fanconi anemia-a patient
manag look puls
differ day make issu manag take puls earlier week observ group
hold rel well remain well financi crisis/aca low sinc chang
dramat declin under-perform stock managed-car group roll quickli
approach level face concern futur industri rampant though acknowledg
risk number remain tough quantifi especi around impact coronaviru could one-tim natur
continu believ compani well-capit abl elimin linger impact via benefit-
design price although would foolish tri call bottom believ long-term fundament remain strong
pleas see updat chart frame valuat last year
host arrowhead manag bruce given vincent anzalon vice-president investor relat
oppenheim healthcar confer share item interest remind arwr target rnai
molecul trim platform technolog clinic valid liver modul hepatocyte-bas target lead asset aro-
phase trial treat patient antitrypsin defici associ liver diseas believ
compani begin phase leverag platform next month may offer us opportun
assess clinic evid trim applic beyond hepatocyt lung potenti muscl indic
pandem unlik slow nda file
wednesday took virtual meet oppenheim annual healthcar confer discuss recent
regulatori progress believ share disproportion affect pandem
compani plan nda file chronic graft-versus-host diseas cgvhd remain track kadmon pre-
nda meet fda proceed plan last week believ nda support efficaci
outcom rockstar supplement safeti data recal rockstar complet enrol mid-august
patient follow month plan announc primari efficaci analysi rockstar
could complet nda file reiter outperform pt
ceo sujal shah discuss recent progress provid busi updat virtual annual healthcar
confer highlight follow discuss potenti path forward nash pbc follow halt
develop seladelpar novemb decid observ abnorm find histolog occur
pre-plan read first batch histolog slide nash trial patient complet treatment
phase nash end-of-treat biopsi nonetheless show strong reduct fibrosi nash resolut
seladelpar lower clinic biomark includ alt/ast/ggt/bilirubin plan independ review sever
expert pathologist quantifi interfac hepat find discuss ahead fda discuss
may provid path forward cash balanc expect burn rate provid potenti runway
recent upgrad outperform perform follow updat outlin path forward
ceo jigar raythatha discuss recent progress anticip catalyst annual healthcar confer
highlight addit bet inhibitor data myelofibrosi mf present eha includ
data patient patient view updat major catalyst base significantli
larger patient number also view updat fibrosi improv potenti diseas modif import
upcom dataset focu regulatori strategi sever option trial initi princip goal trial
pivot data mf indic could unlock via plan trial data on-going data upon file
discret regul similar fedratinib acceler approv base td ti convers baselin
assumpt addit data prostar expect priorit
suffici fund cash
mek combo studi offer best path clinic relev mum registr strategi
idya announc plan evalu monotherapi combo regimen prior choos registr strategi
potenti push timelin launch net view strategi may allow idya reduc
overal size registr program increas probabl demonstr clinic relev respons mum patient
capital-effici like gener addit near-term news flow separ idya disclos phase ii dose mum
therapi studi confirm tablet formul demonstr compar pk capsul use phase dose new
patient includ tablet formul sinc decemb also extend cash runway three month end
expand agreement cruk parg program see
host otonomi otic manag david weber ceo paul cayer cfo cbo oppenheim virtual
healthcar confer share item note remind otic lead product otividex potenti
registration-en phase trial mnire diseas chronic inner ear disord believ success otividex could
address unmet medic need us patient market also like otic pipelin earlier-stag asset
posit compani leverag growth longer term
maintain outperform rate follow manag chang orchard dr bobbi gaspar serv
ceo mr frank thoma presid dr gaspar found ortx in-hous discovery/develop
hematopoet stem cell gene therapi also led acquisit gene therapi asset gsk includ
recal file eu metachromat leukodystrophi mld believ ortx
well posit strengthen commerci network key treatment center given new ceo collabor
research work key stakehold drive newborn screen genet condit near-term launch
follow-on pipelin fully-fund manufactur strong balanc sheet believ ortx offer attract invest
takeaway opco hc day one
day one virtual oppenheim co healthcar confer hc host rang compani
meet investor also abl get updat compani interest coverag two specif
unit therapeut also provid color on-going updat compani
expert regard evolv pandem
investor focu pace phase develop readout happen
feel confid sales/earn number fine relat disrupt
could potenti identifi earn call late april
regard investor seem focus scale pandem could amelior
disrupt biopharma compani could caus non-trivi issu
report revenu par pre-announc result januari reiter revenu
guidanc patient receiv reimburs firdaps report cumul enrol
estim diagnos lem patient prior quarter expect impact assur
adequ product suppli plan extend runway six month cash recent key
busi develop hire focus increas attent evalu extern late-stag orphan drug asset
pipelin expans opportun eye pivot musk-mg data next quarter remain optimist
translat data still queue reiter outperform
tuesday announc result overview upcom mileston clinic site open compani
remain track present first-in-human translat result remind current
evalu phase dose escal cohort recurr metastat head neck cancer r/m scchn sinc
initi last septemb trial advanc third dose cohortand three patient first two cohort remain
treatment call manag emphas pandem materi impair trial enrol
part due high unmet need patient fail prior system therapi key de-risk data expect year
reiter outperform rate pt
weigh impact pandem oxbryta launch
tuesday outlin busi continu strategi respons pandem host virtual investor
meet manag annual healthcar confer temporarili suspend field forc in-person
engag prescrib payer april compani believ action materi impact
timelin ad oxbryta formulari believ impact revenu inevit prospect patient choos
avoid clinic updat model reflect month delay launch investor meet manag
emphas drug suppli api limit factor compani weather near-term disrupt
manufactur reiter outperform pt
ceo paul friedman becki taub cfo marc schneebaum discuss recent progress anticip
catalyst virtual annual healthcar confer highlight impact clinic trial
minim far timelin still track execut recruit maestro-nash trial addit
site on-line progress follow initi dyslipidemia studi open-label portion
still expect read-out lipid non-invas nash biomark late potenti read-across multipl
competitor clinic studi result upcom oca nash fda ad believ uniqu
profil innov clinic develop plan resmetirom provid differenti posit base liver
ceo troy wilson discuss recent progress anticip catalyst virtual annual healthcar confer
highlight includ impact clinic trial minim far timelin still track
addit data hra mutant urotheli carcinoma addit data cmml stratifi
continu enrol registr aim-hn hra r/rhnscc patient could data initi
registr trial advanc nodal t-cell lymphoma initi proof concept trial pancreat cancer
self-impos clinic hold erk inhibitor still potenti lift menin-ml inhibitor
recommend dose support oper
report preliminari adj ep ahead opco/street estim
meanwhil revenu opco/street adj ebitda opco/street
cf vs also explain delay due disagr prior auditor
 current auditor pwc around period revenu adjust attribut last ten year
need recogn importantli adjust affect report result volatil
market certainli partial blame declin addu last month declin around concern
appear way overblown follow-up chang model compani report complet financi result
ceo michael morrissey discuss recent progress anticip catalyst virtual annual healthcar
confer highlight impact on-going trial may see approv ici vegf
may drive demand system therapi aid cabometyx growth expans basket studi nsclc
mcrpc interest cabometyx alreadi show strong data mcrpc orr includ patient post docetaxel
notori hard treat label-en trial enrol six readout potenti four new
indic full steam ahead diversifi beyond rcc readout rcc initi
nsclc data present pivot readout dtc
note
host investor meet ionss brett monia ceo beth hougen cfo note investor interest stock
level appear robust discuss span sever topic includ new ceo vision compani
busi model pipelin prioriti market therapi spinraza waylivra tegsedi commerci strategi given
broad pipelin continu technolog invest oral antisens oligoneucleotid aso deliveri anticip
sever opportun near-term valu creation note execut remain key stori believ offer
diversifi invest opportun clinic commerci valid technolog platform allow manag
make select invest potenti drive organ growth longer term share highlight
meet addit detail page
spoke manag sidelin virtual oppenheim healthcar confer manag provid posit
updat suggest paid case earli march among strongest seen skint launch continu
expect primarili publish studi data build momentum earli adopt advanc
broader reimburs coverag view thesi larg insul near-term disrupt
importantli believ compani taken necessari step protect suppli chain state financi
result confer call last week plan reduc oper cost structur manag clarifi reduct
begin fulli reflect financi perform cash burn expect compar
revenu pre-announc coronaviru impact requir recalibr
strata report rev essenti line pre-announc recur revenu
y/i bright spot quarter threat reduc foot traffic key geographi due coronaviru real
guidanc reflect partial impact alreadi compani highlight wide dispar way coronaviru handl
domest abroad make forecast demand lot problemat henc conserv
drastic take revenu assum return growth
spoke manag sidelin virtual oppenheim healthcar confer manag believ still
earli comment chang demand maci due impact discretionari aci surgeri prior
period disrupt maci/carticel procedur cancel reschedul revenu recogn
compani demand go away push expect impact epicel demand
cloudi chanc competit move perform
downgrad alexion perform remov pt multipl product indic product
new diseas launch occur believ sales/earn strength constitut tough comp henc
updat below-consensu number addit lower price newli launch longer-act ultomiri
soc soliri believ alxn aggress convers strategi prior soliri biosimilar time-frame could
constitut downsid risk updat below-consensu number lastli concern around potenti biosimilar brand
competit next year creat existenti overhang expect revert anytim soon manag
laud revamp pipelin move sidelin
stick biotech fundament market turmoil
follow might describ perfect storm event plummet oil price lock-up expir
comment view overdon weak share highlight key point question
receiv believ disconnect fundament current share level creat signific
opportun despit exit market bull run potenti valuat paradigm shift mid-cap biotech
space earli prepar commerci differenti pnh product plosiv head-to-head clinic
result pois anoth signific pivot clinic catalyst well-capit period stay bullish
revis develop timelin car-t jockey posit pt
monday mustang report earn discuss recent progress manag late anticip
updat mustang academ collabor on-going trial multipl myeloma mm nhl
aml/md nearer-term mustang expect complet ind transfer xscid plan roll
company-sponsor pivot trial newli diagnos patient base discuss manag believ
potenti enter company-sponsor trial believ on-going pandem may
delay certain clinic site open schedul impact patient accrual updat project develop
timelin key program accordingli reiter outperform pt
andexxa save live multipl bleed scenario
abstract virtual meet show mortal benefit andexxa compar treatment factor xa
inhibitor fxai patient experi major bleed mb event retrospect analysi real world patient data show
in-hospit mortal patient treat andexxa vs treat ich patient
treat andexxa vs treat separ analysi match cohort studi
show mortal lower andexxa vs patient overal vs ich subgroup
vs view mortal benefit complementari cost benefit andexxa detail insid
provid busi updat highlight key anticip catalyst rse pivot trial initi expect
follow updat fda cdd pivot marigold top-line data expect
enrol complet trial initi expect manag confirm oper
expect proceed accordingli despit pandem genet epilepsi trial patient use electron diari
remot data collect drug suppli remain top prioriti recent initi coverag review
case studi rse view strongli posit cash balanc provid runway
look forward updat virtual hc confer week
inhal nitric oxid ino potenti coronaviru
beyond announc morn file propos evalu lungfit devic non-ventil compat
devic highlight research conduct rais prospect ino
potenti therapi kerstrom et al journal virolog feb volume beyond also highlight data four
patient studi patient coronaviru ino improv length hospit stay scienc
behind ino select pulmonari vasodil real plasma-discharge-bas devic beyond could real
disruptor cylinder-bas ino space question soon come play
downgrad under-perform hetlioz risk
lower pt move under-perform rate follow announc
hetlioz tasimelteon snda smith-mageni syndrom sm delay manag indic resubmit snda
reason quickli without need addit efficaci studi conserv model sm launch delay
vs earli separ also lower hetlioz revenu estim begin given ode
indic expir composition-of-matt patent expir dec use patent howev
note litig hear continu like compani strong balanc sheet
believ posit manag pursu intern extern capit deploy opportun value-cr
manag care stock remain weak overal market due non-surpris theme polit
environ coronaviru given past outbreak ultim contain compani
abl recov impact futur year price benefit design view one-tim event
littl impact strong long-term fundament busi furthermor recent surg former vice presid
biden elimin signific headlin risk berni sander medicar legisl believ
tuesday primari vote florida key state could prove clincher biden overal long-term manag
care fundament quit strong would take advantag coronavirus-rel weak accumul share
potenti short-term coronaviru impact univers
highlight preliminari field check compani feedback potenti coronaviru impact stock
univers admittedli scientif survey care taken interpret data situat fluid
advis investor brace pronounc impact note hospit restrict sale rep hospit
priorit resourc henc elect procedur across board risk quarantin itali like impact
compani germani implement quarantin larg scale think ou procedur volum take drastic step
number player field check suggest prolong market disrupt beyond june requir drastic recalibr
guidanc across board rel basi view ew less impact
higher risk
second fda alert underscor need fmt altern
thursday fda issu safeti alert fecal microbiota transplant fmt follow six new case report
pathogen coli infect two patient death follow fmt procedur agenc believ pathogen contamin
may origin donor materi suppli stool bank servic explicitli attribut two death
fmt-born pathogen recal fda issu similar safeti commun last year two immunocompromis
patient develop invas bacteri infect follow fmt lead one death seriou safeti event rel
rare fmt incid suggest current stool bank screen practic inadequ justifi develop
product may safer altern fmt reiter outperform
mid-year data could linger doubt upgrad outperform
last week homolog report year-end earn spoke manag recent progress increasingli
bullish prospect head anticip clinic updat phenix upgrad
outperform pt believ readout includ enough patient dispel linger ambigu
effect reduc serum phenylalanin phe patient phenylketonuria pku manag
intend proceed dose expans portion trial mid-year think safe assum upcom readout
could includ result one patient treat high-dos cohort cohort believ
greatest chanc push serum phe goal
updat multicent aml trial readi launch
march marker report year-end result spoke manag final touch made first
company-sponsor trial multitaa aml expect recruit lead-in cohort could commenc within
week recal per protocol first three patient receiv multitaa product manufactur legaci reagent
manag aim resolv partial clinic hold would allow remain three lead-in cohort patient
treat multitaa manufactur newli sourc reagent earli believ marker posit
transit random portion trial marker recent announc equiti facil could extend
runway reiter outperform pt
confer call treatment agent develop part part
may oppenheim med-tech day san francisco ca
may biotech summit featur chemistri life process institut
juli montauk summit emerg life scienc
sept fall summit focus specialti pharma diseas gene therapi new york ny
oct houston oncolog summit md anderson cancer center
healthcar provid manag
